Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Tischkowitz

Showing results (71-80 of 258) with videos related to

Pageof 26
Sort By:
Endocrine Oncology (Bristol, England)|July 12, 2023
Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature reviewEleanor Fewings, Serena Khoo Sert Kim, Alexey Larionov, et al.
Breast Cancer Research and Treatment|September 28, 2011
The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descentStephanie Cote, Suzanna L Arcand, Robert Royer, et al.
Journal of Medical Genetics|November 2, 2010
Germline DICER1 mutations and familial cystic nephromaAmin Bahubeshi, Nebil Bal, Thomas Rio Frio, et al.
British Journal of Cancer|September 18, 2024
Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK BiobankXin Yang, Yujia Wu, Lorenzo Ficorella, et al.
Clinical Genetics|April 20, 2019
The clinical presentation caused by truncating CHD8 variantsSofia Douzgou, Hui Wen Liang, Kay Metcalfe, et al.
Journal of Medical Genetics|March 19, 2011
Germline PALB2 mutation analysis in breast-pancreas cancer familiesZsofia K Stadler, Erin Salo-Mullen, Nelly Sabbaghian, et al.
Human Mutation|January 14, 2012
Rare germline mutations in PALB2 and breast cancer risk: a population-based studyMarc Tischkowitz, Marinela Capanu, Nelly Sabbaghian, et al.
The Lancet. Oncology|August 25, 2011
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyKaren A Gelmon, Marc Tischkowitz, Helen Mackay, et al.
British Journal of Cancer|June 4, 2024
Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practiceOlga Tsoulaki, Marc Tischkowitz, Antonis C Antoniou, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|June 12, 2023
Exploring the barriers to and facilitators of implementing CanRisk in primary care: a qualitative thematic framework analysisStephanie Archer, Francisca Stutzin Donoso, Tim Carver, et al.
Pageof 26

Showing results (71-80 of 258) with videos related to

Sort By:
Pageof 26
Endocrine Oncology (Bristol, England)|July 12, 2023
Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature reviewEleanor Fewings, Serena Khoo Sert Kim, Alexey Larionov, et al.
Breast Cancer Research and Treatment|September 28, 2011
The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descentStephanie Cote, Suzanna L Arcand, Robert Royer, et al.
Journal of Medical Genetics|November 2, 2010
Germline DICER1 mutations and familial cystic nephromaAmin Bahubeshi, Nebil Bal, Thomas Rio Frio, et al.
British Journal of Cancer|September 18, 2024
Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK BiobankXin Yang, Yujia Wu, Lorenzo Ficorella, et al.
Clinical Genetics|April 20, 2019
The clinical presentation caused by truncating CHD8 variantsSofia Douzgou, Hui Wen Liang, Kay Metcalfe, et al.
Journal of Medical Genetics|March 19, 2011
Germline PALB2 mutation analysis in breast-pancreas cancer familiesZsofia K Stadler, Erin Salo-Mullen, Nelly Sabbaghian, et al.
Human Mutation|January 14, 2012
Rare germline mutations in PALB2 and breast cancer risk: a population-based studyMarc Tischkowitz, Marinela Capanu, Nelly Sabbaghian, et al.
The Lancet. Oncology|August 25, 2011
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyKaren A Gelmon, Marc Tischkowitz, Helen Mackay, et al.
British Journal of Cancer|June 4, 2024
Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practiceOlga Tsoulaki, Marc Tischkowitz, Antonis C Antoniou, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|June 12, 2023
Exploring the barriers to and facilitators of implementing CanRisk in primary care: a qualitative thematic framework analysisStephanie Archer, Francisca Stutzin Donoso, Tim Carver, et al.
Pageof 26